

**EXTRAORDINARY GENERAL MEETING SEPTEMBER 17, 2026
OF ARGENX SE
EXPLANATORY NOTES**

The following items on the agenda of the extraordinary general meeting of argenx SE (the "**Company**") shall be discussed and/or put to a vote. The number in the list corresponds to the number on the agenda.

2. Appointment of Thomas M. Brakel as Non-Executive Director to the Board, for a four-year term (voting item)

The Board proposes to nominate Thomas M. Brakel for appointment as a non-executive director ("**Non-Executive Director**") of the board of directors of the Company (the "**Board**") with effect from the date of this general meeting.

The proposed appointment is for a four-year term ending on the day of the annual general meeting of shareholders to be held in 2030. The proposed appointment is in accordance with the Company's articles of association and takes into account the established and preferred composition and profile of the Board as detailed in the Company Profile for Non-Executive Directors.

In making this proposal, the Board has taken into consideration Mr. Brakel's experience, skills, knowledge and expertise built during his career.

Thomas M. Brakel (age 64) was Senior Portfolio Manager at the Federated Hermes Kaufmann Funds from 2003 until 2026, with primary focus on the biotechnology and pharmaceutical sectors.

Before that, he was a biotechnology and pharmaceutical analyst with New Vernon Associates from 2002 until 2003, BioPharma Fund from 2000 until 2002 and Mehta Partners from 1998 until 1999. His U.S. pharmaceutical experience includes six years at Organon Inc. in various positions.

Mr. Brakel has an M.D. degree from the Erasmus University, Rotterdam, The Netherlands and an M.B.A. from Stanford University.

Considering all of the foregoing, the Board nominates Thomas M. Brakel for appointment to the Board for a term of four years (ending on the day of the annual general meeting of shareholders to be held in 2030).

Thomas M. Brakel is considered independent for the purposes of the Dutch Corporate Governance Code 2025. He holds 650 ADSs of ordinary shares of the Company.

3. Appointment of Khurem Farooq as Non-Executive Director to the Board, for a four-year term (voting item)

The Board proposes to nominate Khurem Farooq for appointment as a Non-Executive Director of the Board with effect from the date of this general meeting.

The proposed appointment is for a four-year term ending on the day of the annual general meeting of shareholders to be held in 2030. The proposed appointment is in accordance with the Company's articles of association and takes into account the established and preferred composition and profile of the Board as detailed in the Company Profile for Non-Executive Directors.

In making this proposal, the Board has taken into consideration Khurem Farooq's experience, skills, knowledge and expertise built during his career.

Khurem Farooq (age 59) has over 20 years' drug development and operational leadership experience in the international biotech industry, with expertise across in-licensing, commercialization and business development. He co-founded and currently serves as CEO of Verdiva Bio.

Prior to this, he was co-founder and CEO of Aiolos Bio before its acquisition by GSK in 2024. Mr. Farooq also served as CEO of Gyroscope Therapeutics which was acquired by Novartis in 2021. Previously, he was Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group. At Genentech, he led the commercialization and launch planning of a number of medicines in the Immunology and Ophthalmology area and helped drive several drug candidates through the pipeline as a member of the Late Stage Portfolio Committee. He was also actively involved in business development assessments for the organization. Mr. Farooq began his career at Aventis, holding various roles in sales and marketing.

Mr. Farooq holds an MBA from Aston University as well as a degree in Biological Sciences from Wolverhampton University.

Considering all of the foregoing, the Board nominates Khurem Farooq for appointment to the Board for a term of four years (ending on the day of the annual general meeting of shareholders to be held in 2030).

Khurem Farooq is considered independent for the purposes of the Dutch Corporate Governance Code 2025. He holds 0 ADRs of ordinary shares of the Company.